» Articles » PMID: 17949793

C-reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression in Human Endothelial Cells

Overview
Journal Thromb Res
Date 2007 Oct 24
PMID 17949793
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

C-reactive protein (CRP) is an inflammatory marker which predicts cardiovascular disease. However, it is not fully understood whether CRP has direct effects on endothelial functions and gene expression. The purpose of current study was to determine the effects and molecular mechanisms of CRP on the expression of plasminogen activator inhibitor-1 (PAI-1) in human endothelial cells. Human coronary artery endothelial cells (HCAEC) were treated with CRP at clinically relevant concentrations for different durations. PAI-1 mRNA, protein and enzyme activities were studied. The effects of CRP on MAPK p38 phosphorylation was also studied by Bio-Plex luminex immunoassay. In addition, other types of human endothelial cells isolated from umbilical vein, skin, and lung microvessels were tested. CRP significantly increased PAI-1 mRNA levels in a time- and concentration-dependent manner. The protein level and enzyme activity of PAI-1 in the supernatant of CRP-treated HCAEC cultures were significantly increased. Anti-CD32 antibody effectively blocked CRP-induced PAI-1 mRNA expression. In addition, CRP significantly increased CD32 mRNA levels and enhanced phosphorylation of MAPK p38. Furthermore, antioxidant curcumin dramatically inhibited CRP-induced PAI-1 mRNA expression. The effect of CRP on PAI-1 expression was also confirmed in other types of human endothelial cells. In conclusion, CRP significantly increased the expression of PAI-1 in HCAEC and other human endothelial cells. CRP also increased its receptor CD32 expression which may further enhance its action. CRP-induced PAI-1 expression may be mediated by oxidative stress and p38 signal pathway as antioxidant effectively blocks the effect of CRP on HCAEC.

Citing Articles

"Going with the flow" in modeling fibrinolysis.

Whyte C, Mutch N Front Cardiovasc Med. 2022; 9:1054541.

PMID: 36531720 PMC: 9755328. DOI: 10.3389/fcvm.2022.1054541.


Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19.

Wang J, Choy K, Lim H, Ho P J Pers Med. 2022; 12(10).

PMID: 36294850 PMC: 9605464. DOI: 10.3390/jpm12101711.


Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease.

Schmid F, Chao C, Dabritz J Int J Mol Sci. 2022; 23(13).

PMID: 35806292 PMC: 9266732. DOI: 10.3390/ijms23137287.


A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.

Morrow G, Whyte C, Mutch N Front Cardiovasc Med. 2021; 8:653655.

PMID: 33937363 PMC: 8085275. DOI: 10.3389/fcvm.2021.653655.


Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells.

Henze L, Luong T, Boehme B, Masyout J, Schneider M, Brachs S Aging (Albany NY). 2019; 11(15):5445-5462.

PMID: 31377747 PMC: 6710049. DOI: 10.18632/aging.102130.


References
1.
Pepys M . C-reactive protein fifty years on. Lancet. 1981; 1(8221):653-7. DOI: 10.1016/s0140-6736(81)91565-8. View

2.
Verma S, Wang C, Weisel R, Badiwala M, Li S, Fedak P . Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003; 35(4):417-9. DOI: 10.1016/s0022-2828(03)00042-7. View

3.
Bisoendial R, Kastelein J, Levels J, Zwaginga J, van den Bogaard B, Reitsma P . Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005; 96(7):714-6. DOI: 10.1161/01.RES.0000163015.67711.AB. View

4.
Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363-9. DOI: 10.1161/01.cir.0000053730.47739.3c. View

5.
Bharadwaj D, Stein M, Volzer M, Mold C, Du Clos T . The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med. 1999; 190(4):585-90. PMC: 2195602. DOI: 10.1084/jem.190.4.585. View